Back to Search
Start Over
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
- Source :
-
Haematologica [Haematologica] 2017 Apr; Vol. 102 (4), pp. 765-772. Date of Electronic Publication: 2016 Dec 23. - Publication Year :
- 2017
-
Abstract
- The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance therapy with obinutuzumab alone, in previously untreated patients with follicular lymphoma. Assignment to chemotherapy was decided on a per-center basis before the patients' enrollment. Patients (n=81) received four to six cycles of obinutuzumab plus bendamustine every 4 weeks or six to eight cycles of obinutuzumab plus CHOP every 3 weeks. Patients with an end-of-treatment response were eligible for obinutuzumab maintenance therapy every 3 months for 2 years or until disease progression. Induction treatment was completed by 90% of patients in the obinutuzumab plus bendamustine group and 95% in the obinutuzumab plus CHOP group, while maintenance was completed by 81% and 72% of patients, respectively. All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2. The most common hematologic adverse event was grade 3/4 neutropenia (36% during induction and 7% during maintenance). One treatment-related death occurred during the maintenance phase. At the end of induction, 94% of patients had achieved an overall response, with complete response based on computed tomography in 36%. The progression-free survival rate at 36 months was 90% in the obinutuzumab plus bendamustine group and 84% in the obinutuzumab plus CHOP group. These results demonstrate that induction therapy with obinutuzumab plus bendamustine or obinutuzumab plus CHOP, followed by obinutuzumab maintenance, is associated with tolerable safety and promising efficacy. This study is registered at ClinicalTrials.gov as NCT00825149.<br /> (Copyright© Ferrata Storti Foundation.)
- Subjects :
- Adult
Aged
Antibodies, Monoclonal, Humanized administration & dosage
Antineoplastic Combined Chemotherapy Protocols adverse effects
Bendamustine Hydrochloride administration & dosage
Cyclophosphamide adverse effects
Cyclophosphamide therapeutic use
Doxorubicin adverse effects
Doxorubicin therapeutic use
Drug Monitoring
Female
Follow-Up Studies
Humans
Induction Chemotherapy
Lymphoma, Follicular mortality
Lymphoma, Follicular pathology
Maintenance Chemotherapy
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Prednisone adverse effects
Prednisone therapeutic use
Survival Analysis
Treatment Outcome
Tumor Burden
Vincristine adverse effects
Vincristine therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Lymphoma, Follicular drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 102
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 28011903
- Full Text :
- https://doi.org/10.3324/haematol.2016.152272